+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole



13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole



Alimentary Pharmacology and Therapeutics 30(3): 294-300



(13)CO(2) is produced on metabolism of (13)C-labelled-pantoprazole ([(13)C]-pantoprazole) by CYP2C19. To investigate whether the [(13)C]-pantoprazole breath test can predict CYP2C19 status and efficacy of proton pump inhibitors (PPIs) in Japanese. We classified 110 healthy volunteers as rapid metabolizers (RM), intermediate metabolizers (IM) or poor metabolizers (PM) of CYP2C19 by genotyping. Breath samples were collected at 10-min intervals for 60 min after dosing with 100 mg [(13)C]-pantoprazole. Changes in the carbon isotope ratios ((13)CO(2)/(12)CO(2)) in carbon dioxide in breath samples were measured and expressed as a delta-over-baseline (DOB) ratio ( per thousand). Of the 110 subjects, twenty-two randomly selected subjects underwent intragastric pH monitoring on day 7 of dosing with 30 mg of lansoprazole. The DOB values of RMs were the highest and those of PMs the lowest of the three groups. Statistically significant differences were observed in the area-under-the-curve (AUC)(20-60 min) of DOB among the three groups. The mean 24-h intragastric pHs attained by lansoprazole 30 mg for 7 days were inversely correlated with the AUC(20-60 min) of DOB. [(13)C]-pantoprazole breath test can easily estimate the individual activity of CYP2C19 and predict the efficacy of a PPI (i.e. lansoprazole). This test would be useful for individualized medicine with a PPI.

(PDF emailed within 0-6 h: $19.90)

Accession: 051027340

Download citation: RISBibTeXText

PMID: 19459830

DOI: 10.1111/j.1365-2036.2009.04044.x


Related references

The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metabolism and Disposition: the Biological Fate of Chemicals 39(11): 2020-2033, 2012

Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole. Alimentary Pharmacology and Therapeutics 20(1): 117-122, 2004

Effect of high dose citric acid on proton pump inhibitor induced false negative 13c urea breath tests comparison between omeprazole, pantoprazole and lansoprazole. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No 452, 2003

The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole- 13 C breath test in GERD patients: clinical relevance for personalized medicine. Journal of Breath Research 10(4): 046017, 2017

Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity. Journal of Breath Research 10(1): 017104, 2016

Is (+)-[13C]-pantoprazole better than (±)-[13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity?. Journal of Breath Research 7(1): 016001, 2013

Rapid identification of hepatic CYP2C19 activity using the C-13-pantoprazole breath test in healthy volunteers genotyped for CYP2C19.. 2008

The proton pump inhibitor lansoprazole improves the skeletal phenotype in dystrophin deficient mdx mice. Plos One 8(7): E66617, 2014

Metabolism disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype. Clinical Pharmacology & Therapeutics 62(6): 619-628, 1997

Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype. Clinical Pharmacology and Therapeutics 62(6): 619-628, 1998

2 new proton pump inhibitors. Possibilities of pantoprazole and lansoprazole. Der Internist 37(9): 944-9; Discussion 949, 1996

Activity of Lansoprazole (new proton pump inhibitor) against Helicobacter pylori and its therapeutic efficacy. Nihon Rinsho. Japanese Journal of Clinical Medicine 51(12): 3261-3266, 1993

Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. European Journal of Gastroenterology and Hepatology 8 Suppl 1: S21-S25, 1996

Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment. European Journal of Pediatrics 177(1): 69-77, 2017

Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole--a preliminary study. Chirality 9(1): 17-21, 1997